Mr. Joel Shacker reports

CORE ONE LABS COMMENDS STUDY EXPLORING PSYCHEDELICS' EFFICACY IN PROVIDING RELIEF FOR CHRONIC PAIN CONDITIONS

Core One Labs Inc. applauds a recent survey study published in the European Journal of Pain, which suggests that psychedelic substances could offer potential therapeutic value in addressing specific chronic pain conditions.

By conducting an extensive survey among 170 individuals dealing with chronic pain and who met the inclusion criteria, the research aimed to uncover insights into the effectiveness of conventional treatments, full psychedelic doses and psychedelic microdoses on five prevalent chronic pain conditions: fibromyalgia, arthritis, migraine, tension-type headache and sciatica. These conditions were carefully selected based on consistent diagnostic criteria.

The outcomes of the survey were promising as participants, with the exception of those experiencing sciatica, consistently reported experiencing superior pain relief through the use of psychedelics compared with conventional medications across all the studied conditions. Particularly noteworthy was the observation that full psychedelic doses outperformed traditional treatments in terms of effectiveness. Microdoses also displayed significant potential, delivering substantial relief for migraines and comparable relief for the other chronic pain conditions investigated.

The study's significance lies in its contribution to the growing body of evidence supporting the therapeutic role of psychedelic substances and its analgesic effects among individuals suffering from fibromyalgia, arthritis, migraine, tension-type headache and sciatica. The authors of the study believe the findings hold tremendous implications for the advancement of future research endeavours concerning the practical utilization of psychedelics for pain management.

Core One Labs acknowledges the importance of this research as a stepping stone for further advancements in the field of chronic pain management, and remains steadfast in supporting and encouraging any further studies and breakthroughs exploring psychedelic interventions aimed at addressing pain.

Engagement of Stride Report

The company also announces that further to its news release of July 19, 2023, the company has engaged Stride Report Inc., an arm's-length party to the company, to provide marketing and investor awareness services. The company has agreed to pay to Stride a monthly non-refundable fee of $10,000, plus applicable taxes, per month, for a period of four months. The services will include investor relations, creation of content, strategic planning, digital advertisement placement, and overseeing progress and results of digital campaigns. Consideration offered to Stride does not include any securities of the company. Aside from this engagement, the company does not have any relationship with stride and Raafat Nasser, chief executive officer of Stride. Stride's business address is located 1120, 625 Howe St., Vancouver, B.C., V6C 1T2, e-mail is raafat@stride.report, telephone number is 604-710-7318.

We seek Safe Harbor.